Neuralink, the neurotech startup co-founded by Elon Musk, announced Thursday it has received approval from the Food and Drug Administration to conduct its first in-human clinical study.

Neuralink is building a brain implant called the Link, which aims to help patients with severe paralysis control external technologies using only neural signals. This means patients with severe degenerative diseases like ALS could eventually regain their ability to communicate with loved ones by moving cursors and typing with their minds.

Elon Musk’s company Neuralink announced Thursday that it received approval from the Food and Drug Administration (FDA) to conduct its first-in-human clinical study.

"We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study," the company said in a tweet.

Musk helped co-found Neuralink, a neurotechnology company working to develop brain implants that could someday help people who are paralyzed walk again, as well as help with other neurological issues.

Neuralink has announced that the U.S. Food and Drug Administration (FDA) has approved the launch of its first clinical study in humans.

"We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study!" Neuralink's official Twitter account wrote on Thursday.(opens in a new tab) "This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people."